MONMOUTH JUNCTION, NJ–(Jul 26, 2013) – CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company working to save lives through blood purification, announced that it has been selected to make a presentation of its HemoDefend™ blood purification technology at the Military Health System Research Symposium (MHSRS), the premier U.S. scientific meeting focused on medical advances that address the unique medical needs of the warfighter.
HemoDefend™ is a novel blood purification technology designed to reduce a broad range of dangerous contaminants, such as free hemoglobin, antibodies, bioactive lipids, and cytokines, in transfused blood products that can cause potentially deadly transfusion reactions and adverse outcomes in patients receiving packed red blood cells and platelets. It is based upon CytoSorbents’ highly biocompatible porous polymer bead technology platform and can be implemented either as an in-line filter at the point of transfusion, or in an innovative “Beads-in-a-Bag” configuration where the polymer beads purify blood directly in the blood storage bag.
“Blood is a life-saving therapy not only for our wounded warfighters, but for millions of civilians each year. Nearly 85 million units of packed red blood cells and 10 million platelet units are transfused worldwide annually. But receiving blood is not without risk and can sometimes lead to more harm than good,” said Dr. Phillip Chan, CEO of CytoSorbents. “By broadly reducing the contaminants in blood that can cause transfusion reactions and bad outcomes, HemoDefend™ represents one of the newest innovations in improving the quality and safety of the blood supply.”
The MHSRS conference, which attracted more than 1,500 participants last year, will be held at the Harbor Beach Marriott Hotel in Fort Lauderdale, Florida, from August 12-15, 2013. Dr. Chan will present the HemoDefend™ technology platform on Monday, August 12, 2013 at 3:40PM. CytoSorbents will also be showcasing its blood purification technologies, including CytoSorb® and HemoDefend™, during the conference in the exhibition hall. HemoDefend™ is under advanced development and not yet approved for commercial sale.
The MHSRS conference provides a collaborative environment for military medical care providers and scientists from the US Department of Defense (including all branches of the military), academia, and industry, as well as those from allied countries, to discuss and address the advancement of research and health care development in areas of Combat Casualty Care, Military Operational Medicine, Clinical and Rehabilitative Medicine, and Military Infectious Disease Research Programs. (https://www.mhsrs.org).
About CytoSorbents Corporation
CytoSorbents is a critical care focused therapeutic device company specializing in blood purification. CytoSorb®, the Company’s flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine filter, designed to reduce the “cytokine storm” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the mortality is extremely high, yet no effective treatments exist. The goal of CytoSorb® is to prevent or treat multiple organ failure, the cause of nearly half of all deaths in the intensive care unit, with little available to improve clinical outcome. CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company’s website: http://www.cytosorbents.com
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management’s current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. Risk factors are detailed in the Company’s Form 10-K filed with the SEC on April 3, 2013, which is available at http://www.sec.gov.
- Company Contact:
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823
Email ContactInvestor Contact:
Alliance Advisors, LLC
(914) 669-0222 x201